The DOI matches its Crossref record.
CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma
Open accessAbstract
Most hepatocellular carcinoma (HCC) therapies fail to target cancer stem cells (CSCs) and monitor cancer progression or regression. The purpose of this study was to evaluate the possibility of cancer imaging and simultaneously monitoring targeted therapy in a single animal by anti-CD44 antibody-mediated liposomal nanoparticle. In this study, an in situ liver tumor model was applied for therapy by injecting 1.0 × 10(6) HepG2 cells carrying a reporter system encoding a double fusion (DF) reporter gene consisting of firefly luciferase (Fluc) and green fluorescent protein (GFP) into the liver of NOD/SCID mice. A strategy was developed which specifically targeted HCC via anti-CD44 antibody-mediated liposomal nanoparticle delivery, loaded of either doxorubicin (Dox) or a triple fusion (TF) gene containing the herpes simplex virus truncated thymidine kinase (HSV-ttk) and renilla luciferase (Rluc) and red fluorescent protein (RFP). The NOD/SCID mice were subsequently treated with ganciclovir (GCV) and the growth status of tumor was monitored by optical bioluminescence imaging (BLI) of Fluc and specific targeting of the liposomal nanoparticle was tracked by Rluc imaging. CD44 antibody-mediated liposomal nanoparticle, loaded of TF plasmids, were shown to be useful for monitoring and evaluating targeting efficacy and gene therapy by non-invasive molecular imaging. Here, we demonstrate the time intensive preclinical steps involved in molecular target identification, validation, and characterization by dual molecular imaging. This targeted and traceable therapeutic strategy has potential advantages to overcome the problems of conventional tumor therapy and may open a new application for the treatment of HCC by targeting CSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597
Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery
Wang, F., Wang, Y., Zhang, X., Zhang, W., Guo, S., & Jin, F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.020 · Cited by 377
Jiang, T., Zhang, Z., Zhang, Y., Lv, H., Zhou, J., Li, C., Hou, L., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.027 · Cited by 359
Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics
Gong, F., Yang, N., Wang, X., Zhao, Q., Chen, Q., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100851 · Cited by 359
Self-citationRole of prostaglandin E2 in tissue repair and regeneration
Cheng, H., Huang, H., Guo, Z., Chang, Y., & Li, Z. (2021) · Theranostics · doi:10.7150/thno.63396 · Cited by 315
Self-citation
Metadata
- Authors
- Wang, L., Su, W., Liu, Z., Zhou, M., Chen, S., Chen, Y., Lu, D., Liu, Y., Fan, Y., Zheng, Y., Han, Z., Kong, D., Wu, J. C., Xiang, R., & Li, Z.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 33
- Issue
- 20
- Pages
- 5107-5114
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2041685488
- Cited by
- 193
- References
- 0
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. https://app.cochat.ai/papers/10.1016/j.biomaterials.2012.03.067
- The paper
- Wang, L., Su, W., Liu, Z., Zhou, M., Chen, S., Chen, Y., Lu, D., Liu, Y., Fan, Y., Zheng, Y., Han, Z., Kong, D., Wu, J. C., Xiang, R., & Li, Z. (2012). CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials. https://doi.org/10.1016/j.biomaterials.2012.03.067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.